cancer

Vast majority of people survive common thyroid cancer even without treatment

Wednesday, June 02, 2010 by: S. L. Baker, features writer
Tags: thyroid cancer, treatment, health news

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Cannabis dissolves cancerous tumor in young infant, deemed a 'miracle baby' by physician
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Monsanto's seed imperialism halted in Canada thanks to massive protests
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
Why flu shots are the greatest medical fraud in history
Governments seize colloidal silver being used to treat Ebola patients, says advocate
Flu vaccine kills 13 in Italy; death toll rises
The 21 curious questions we're never allowed to ask about vaccines
CDC admits it has been lying all along about Ebola transmission; "indirect" spread now acknowledged

Delicious
(NaturalNews) Mainstream medicine has reported in recent years that the incidence of papillary thyroid cancer -- the most common form of thyroid malignancy -- is growing at an alarming rate. In fact, the number of people diagnosed with this form of cancer, which typically arises as an irregular mass in an otherwise normal thyroid gland, has tripled over the past three decades. But a new study by Dartmouth Medical School researchers has come up with good news about this so-called "epidemic".

First of all, the cases of papillary thyroid cancer have most likely only appeared to increase -- simply because of the huge surge in the use of ultrasound tests and biopsies. And it turns out the vast majority of people with this cancer survive it just fine, even if they receive no treatment at all.

Background information included in the study, which was just published in the May issue of the Archives of Otolaryngology, Head & Neck Surgery explains that papillary thyroid cancer is commonly found on autopsy among people who died of other causes. "Studies published as early as 1947 demonstrated it, and more recently, a report has shown that nearly every thyroid gland might be found to have a cancer if examined closely enough," the study authors wrote. "The advent of ultrasonography and fine-needle aspiration biopsy has allowed many previously undetected cancers to be identified, changing the epidemiology of the disease. Over the past 30 years, the detected incidence of thyroid cancer has increased three-fold, the entire increase attributable to papillary thyroid cancer and 87% of the increase attributable to tumors measuring less than 2 centimeters."

Louise Davies, M.D., of Dartmouth Medical School and Gilbert Welch, M.D., of the Dartmouth Institute for Health Policy and Clinical Practice, investigated thyroid cancer cases and gathered data about the patients' treatment from National Cancer Institute (NCI) registries. Then they looked for causes of death through the National Vital Statistics System.

The researchers found that out of 35,663 people with papillary thyroid cancer which had not spread to the lymph nodes or other areas at diagnosis, 440 (1.2 percent) did not undergo immediate, definitive treatment (i.e. surgery). Six years later, follow-up research showed that only six of these patients had died of their cancer. This was virtually the same rate of cancer deaths among the 35,223 individuals who did undergo treatment, which involved having part or all of their thyroids removed.

Specifically, the 20-year survival rate from cancer was 97 percent for those who did not receive treatment and 99 percent for those who did -- a slight difference the Dartmouth scientists noted was not statistically significant. Bottom line: almost everyone diagnosed with papillary thyroid cancer of any size confined to the thyroid survived whether they had treatment or not.

"Thus, clinicians and patients should feel comfortable considering the option to observe for a year or longer cancers that fall into this category," the researchers concluded.

For more information:
http://www.ncbi.nlm.nih.gov/pubmed/20479371

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.